Northwind Pharmaceuticals recalled Sulfamethoxazole and Trimethoprim Tablets on August 20, 2025. The recall affects several lot numbers due to a foreign substance found in packaging. Consumers should stop using the product and seek guidance immediately.
Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.
Consumers and healthcare providers should stop using this product immediately. Contact Northwind Pharmaceuticals LLC or your healthcare provider for guidance. Notification method: Letter
The recall includes Sulfamethoxazole and Trimethoprim Tablets, USP 800mg / 160mg Double Strength. Affected packaging includes 6-count (NDC 51655-307-87), 10-count (NDC 51655-307-53), 14-count (NDC 51655-307-84), and 20-count bottles (NDC 51655-307-20). A total of 2,295 bottles are recalled.
The recall was initiated due to the detection of a micro-organism on a specific lot of auxiliary polyester coil used in product packaging. No micro-organism was detected on any of the tablets themselves.
There have been no reported injuries or incidents associated with the contaminated product. The presence of the micro-organism poses a high risk to consumer safety.
Consumers and healthcare providers should immediately stop using the recalled product. Contact Northwind Pharmaceuticals LLC or consult a healthcare provider for further guidance.
For more information, contact Northwind Pharmaceuticals at their official website or through the FDA recall link.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.